These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 27769174)

  • 1. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.
    Sineke T; Evans D; Schnippel K; van Aswegen H; Berhanu R; Musakwa N; Lönnmark E; Long L; Rosen S
    Health Qual Life Outcomes; 2019 May; 17(1):94. PubMed ID: 31151398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.
    Daniels JF; Khogali M; Mohr E; Cox V; Moyo S; Edginton M; Hinderaker SG; Meintjes G; Hughes J; De Azevedo V; van Cutsem G; Cox HS
    PLoS One; 2015; 10(11):e0142873. PubMed ID: 26555134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substantially Higher and Earlier Occurrence of Anti-Tuberculosis Drug-Related Adverse Reactions in HIV Coinfected Tuberculosis Patients: A Matched-Cohort Study.
    Matono T; Nishijima T; Teruya K; Morino E; Takasaki J; Gatanaga H; Kikuchi Y; Kaku M; Oka S
    AIDS Patient Care STDS; 2017 Nov; 31(11):455-462. PubMed ID: 29087745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
    Pietersen E; Anderson K; Cox H; Dheda K; Bian A; Shepherd BE; Sterling TR; Warren RM; van der Heijden YF
    PLoS One; 2023; 18(2):e0281097. PubMed ID: 36780443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
    Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
    AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013.
    Chingonzoh R; Manesen MR; Madlavu MJ; Sopiseka N; Nokwe M; Emwerem M; Musekiwa A; Kuonza LR
    PLoS One; 2018; 13(8):e0202469. PubMed ID: 30133504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.
    Sagwa E; Ruswa N; Musasa JP; Mantel-Teeuwisse AK
    Drug Saf; 2013 Nov; 36(11):1087-96. PubMed ID: 23917883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa.
    Mokhele I; Jinga N; Berhanu R; Dlamini T; Long L; Evans D
    BMC Pregnancy Childbirth; 2021 Jun; 21(1):453. PubMed ID: 34182944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.
    Isaakidis P; Varghese B; Mansoor H; Cox HS; Ladomirska J; Saranchuk P; Da Silva E; Khan S; Paryani R; Udwadia Z; Migliori GB; Sotgiu G; Reid T
    PLoS One; 2012; 7(7):e40781. PubMed ID: 22792406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa.
    Mohr E; Cox V; Wilkinson L; Moyo S; Hughes J; Daniels J; Muller O; Cox H
    Trans R Soc Trop Med Hyg; 2015 Jul; 109(7):425-32. PubMed ID: 25979526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective record review of pregnant women treated for rifampicin-resistant tuberculosis in South Africa.
    Walt MV; Masuku S; Botha S; Nkwenika T; Keddy KH
    PLoS One; 2020; 15(9):e0239018. PubMed ID: 32970722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria.
    Oladimeji O; Isaakidis P; Obasanya OJ; Eltayeb O; Khogali M; Van den Bergh R; Kumar AM; Hinderaker SG; Abdurrahman ST; Lawson L; Cuevas LE
    PLoS One; 2014; 9(4):e94393. PubMed ID: 24722139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.
    Nagu TJ; Aboud S; Mwiru R; Matee MI; Rao M; Fawzi WW; Zumla A; Maeurer MJ; Mugusi F
    Int J Infect Dis; 2017 Mar; 56():39-44. PubMed ID: 28161460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T; Ncayiyana J; Padanilam X; Nyasulu PS
    BMC Infect Dis; 2015 Oct; 15():478. PubMed ID: 26511616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    J Antimicrob Chemother; 2017 Jul; 72(7):1871-1879. PubMed ID: 28419314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.